AliveCor’s KardiaMobile 6L Receives FDA’s Clearance as Six-Lead Personal ECG Device

 AliveCor’s KardiaMobile 6L Receives FDA’s Clearance as Six-Lead Personal ECG Device

AliveCor’s KardiaMobile 6L Receives FDA’s Clearance as Six-Lead Personal ECG Device

Shots:

  • KardiaMobile is the personal ECG device delivering multi-dimensional insight into a patient’s heart, connected with the Kardia app used to detect AF, bradycardia, tachycardia, and normal rhythm in an ECG without using gels/wires
  • Kardia 6-lead smartphone ECG tracings can diagnose heart rhythm and conduction abnormalities which are leading indicators of cardiovascular disease and is expected to be available in Jun’19
  • The KardiaMobile six-lead device contains two electrodes on the top of the device & one on the bottom, placing their thumbs on two top electrodes with a bottom electrode is placed on left knee/ankle, forming Einthoven Triangle, providing better insights into electrical activity in the heart

Click here to read full press release/ article | Ref: PRNewsWire | Image: Research Gate

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post